XML 50 R20.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Collaboration Arrangements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2012
Collaboration Arrangements |
Schedule of common stock shares purchased in private placements by the affiliate of GSK |
|  | Through September 30, 2012 |
|  | Common Stock Shares Purchased |  | Aggregate Amounts (in thousands) |
Purchase dates |  |  |  |  |
February 24, 2011 |  | 152,278 |  | $ | 3,609 |
May 3, 2011 |  | 261,299 |  | $ | 6,689 |
August 2, 2011 |  | 102,466 |  | $ | 2,020 |
November 1, 2011 |  | 58,411 |  | $ | 1,298 |
February 14, 2012 |  | 88,468 |  | $ | 1,603 |
August 3, 2012 |  | 316,334 |  | $ | 8,924 |
Schedule of upfront license fees and milestone payments received from GSK under the LABA collaboration and strategic alliance agreements |
|  | Through September 30, 2012 |
(in thousands) |  | Upfront Fees |  | Milestone Payments |  | Total |
GSK Collaborations |  |  |  |  |  |  |
LABA collaboration(1) |  | $ | 10,000 |  | $ | 50,000 |  | $ | 60,000 |
Strategic alliance agreement |  | 20,000 |  | — |  | 20,000 |
Strategic alliance—LAMA license(2) |  | 5,000 |  | 3,000 |  | 8,000 |
Strategic alliance—MABA program license |  | 6,000 |  | 16,000 |  | 22,000 |
Total |  | $ | 41,000 |  | $ | 69,000 |  | $ | 110,000 |
(1) The Company does not expect to be eligible for any additional milestones under this collaboration. (2) In August 2004, GSK exercised its right to license the Company’s LAMA program pursuant to the terms of the strategic alliance. In 2009, GSK returned the program to the Company.
Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements |
|  | Three Months Ended September 30, |  | Nine Months Ended September 30, |
(in thousands) |  | 2012 |  | 2011 |  | 2012 |  | 2011 |
GSK Collaborations |  |  |  |  |  |  |  |  |
LABA collaboration |  | $ | 907 |  | $ | 1,270 |  | $ | 2,722 |  | $ | 3,811 |
Strategic alliance agreement |  | — |  | 489 |  | — |  | 1,858 |
Strategic alliance—MABA program license |  | 523 |  | 621 |  | 1,569 |  | 1,625 |
Total revenue |  | $ | 1,430 |  | $ | 2,380 |  | $ | 4,291 |  | $ | 7,294 |
Schedule of revenue recognized under the Astellas collaboration agreement |
|  | Three Months Ended September 30, |  | Nine Months Ended September 30, |
(in thousands) |  | 2012 |  | 2011 |  | 2012 |  | 2011 |
Recognition of deferred revenue |  | $ | — |  | $ | — |  | $ | 125,819 |  | $ | — |
Amortization of deferred revenue |  | — |  | 3,244 |  | — |  | 9,731 |
Royalties from net sales of VIBATIV® |  | — |  | 807 |  | — |  | 2,131 |
Proceeds from VIBATIV® delivered to Astellas |  | — |  | — |  | — |  | 1,171 |
Cost of VIBATIV® delivered to Astellas |  | — |  | — |  | — |  | (1,177 | )
Astellas-labeled product sales allowance |  | — |  | — |  | (150 | ) | — |
Total net revenue |  | $ | — |  | $ | 4,051 |  | $ | 125,669 |  | $ | 11,856 |

X
- Definition Tabular disclosure of the common stock shares and the aggregate value purchased in private placements by an affiliate of an entity with which there is a collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborationArrangementsCommonStockActivityTableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | thrx_CollaborationArrangementsDisclosureAbstract
Namespace Prefix: | thrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue recognition by the entity related to Astella collaboration agreement. + References No definition available. + Details
Name: | thrx_CollaborativeArrangementRevenueRecognitionAstellaCollaborationTableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the upfront fees and milestone payments received by the entity pursuant to collaboration and strategic alliance agreements related to long-acting beta-2 agonist (LABA) products during the period. + References No definition available. + Details
Name: | thrx_ScheduleOfCollaborativeArrangementsUpfrontFeesAndMilestonePaymentsReceivedTableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the revenue recognized through amortization of the deferred upfront fees and milestone payments received by the entity under the collaboration and strategic alliance agreements related to long-acting beta-2 agonist (LABA) products during the period. + References No definition available. + Details
Name: | thrx_ScheduleOfCollaborativeArrangementsUpfrontFeesAndMilestonePaymentsRevenueRecognizedLABATableTextBlock
Namespace Prefix: | thrx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration